sb 203580 has been researched along with s-allylcysteine in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (s-allylcysteine) | Trials (s-allylcysteine) | Recent Studies (post-2010) (s-allylcysteine) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 241 | 1 | 123 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basu, A; Chakraborti, U; Chatterjee, S; Chowdhury, KD; Ghosh, P; Patra, D; Sadhukhan, GC; Sengupta, D | 1 |
1 other study(ies) available for sb 203580 and s-allylcysteine
| Article | Year |
|---|---|
Association of p38MAPK-p53-Fas aggregation in S-allyl cysteine mediated regulation of hepatocarcinoma.
Topics: Animals; Antineoplastic Agents; Caspases; Cysteine; Fas Ligand Protein; fas Receptor; Hep G2 Cells; Humans; Imidazoles; Liver Neoplasms, Experimental; Male; Mice; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Tumor Suppressor Protein p53 | 2019 |